-
Mashup Score: 0Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas - 2 year(s) ago
Squamous cell carcinoma is a histologically defined subtype of lung cancer that exhibits a complex genetic landscape. [1,2] The genomics of squamous cell lung cancer are notable for the absence of certain targetable genomic alterations found commonly in lung adenocarcinoma (e.g. EGFR, ALK, etc.). [1–3] Instead, an array of other genomic alterations have been identified including numerous gene…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Interventions to improve lung cancer screening among racially and ethnically minoritized groups: A scoping review - 2 year(s) ago
Lung cancer screening (LCS) decreases lung cancer related mortality among high-risk people who smoke cigarettes and has been endorsed by the US Preventive Services Task Force (USPSTF) since 2013 [1]. However, adoption of LCS has been limited with an estimated 5.7 % of the eligible population having been screened in the U.S. as of 2020 [2]. Even with this low uptake, racial and ethnic disparities…
Source: Lung CancerCategories: Latest Headlines, PulmonologyTweet-
#Interventions to improve #lungcancer #screening among racially and ethnically minoritized groups: A scoping review #lungs https://t.co/C8t5KtY2Dk https://t.co/4FqjyM07o9
-
-
Mashup Score: 0Economic impact of using risk models for eligibility selection to the International lung screening Trial - 2 year(s) ago
Three large randomized trials have shown that lung cancer screening with low-dose computed tomography (LDCT) can reduce lung cancer mortality by more than 20 % [1–3]. In 2013 the US Preventative Services Task Force (USPSTF) gave lung screening a grade “B” recommendation for individuals between ages 55–80, with at least 30 pack-years of smoking history and ≤ 15 years of smoking abstinence [4]. The…
Source: Lung CancerCategories: Latest Headlines, PulmonologyTweet-
#Economic impact of using #risk #models for eligibility selection to the International #lung #screening Trial https://t.co/FvDrzYyd1j https://t.co/OkJDdXlzZB
-
-
Mashup Score: 0
At diagnosis, approximately one-third of patients with non-small cell lung cancer (NSCLC) present with potentially resectable disease [1-4]. Adjuvant cisplatin-based chemotherapy is recommended in patients with resected tumor-node-metastasis 8th edition stage II–IIIA disease and/or patients with tumor size > 4 cm [5]; however, new options are becoming available for patients.
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Review @LungCaJournal discusses endpoints in early stage #EGFR mutant NSCLC. While OS has been our historic standard, there is growing acceptance for surrogates such as DFS, EFS, pCR, MPR and possibly ctDNA-based MRD. But we still need validation. https://t.co/WwljYhPMqy
-
-
Mashup Score: 3
Epidermal growth factor receptor (EGFR) mutations (EGFRm) are known oncogene drivers in non-small cell lung cancer (NSCLC) [1]. Up to 41% of Asians, 19% of Caucasians, and 29% of African Americans diagnosed with NSCLC have been reported to harbor EGFRm [2]. Among patients with NSCLC, approximately 45% and 40% of patients have sensitizing mutations in exon 19 (exon 19 deletion) or 21 (L858R),…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Some insights into #EGFR testing @LungCaJournal: 78% received results ≤2 weeks, 37% of pts began therapy before receiving EGFR results. Use of first-line TKI in this study was 86% in Canada, only 53% in US. Lots of room for improvement here... https://t.co/ARvO5SE26V
-
-
Mashup Score: 1
Lung cancer is one of the most frequent types of cancer and is the most common cause of death from cancer [1]. The five-year survival rate ranges from 4.2% to 55% with a median rate of 20% depending on the stage at diagnosis and the presence or not of an activating oncogenic alteration [2,3]. Non-small Cell Lung Cancer (NSCLC) accounts for 85-90% of lung cancers [4], adenocarcinoma representing…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Guidance on managing cutaneous toxicity of amivantamab (#EGFR and #MET bispecific, approved for #EGFRex20 NSCLC) from Drs. Clémence Basse and @nicogirardcurie at Anti-cancer Center Institut Curie in Paris now @LungCaJournal. #LCSM https://t.co/4cnwvnm0qf
-
-
Mashup Score: 0Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab? - 3 year(s) ago
Malignant pleural mesothelioma (MPM) is a rare malignant tumor arising from the mesothelial cells of the pleura. It is mainly caused by exposure to asbestos, with a latency time between exposure and diagnosis of 30 to 50 years.(1)
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Some things to delve into here, with rising use of #immunotherapy for malignant mesothelioma: 'Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?' in @LungCaJournal https://t.co/3ESiFaSFLF #ESMO22 #ESMO2022 #mesothelioma https://t.co/hm4Cgc4Bke
-
-
Mashup Score: 1Incidental findings in low dose CT lung cancer screening of high-risk smokers: results from the Manchester Lung Health Check pilot - 3 year(s) ago
Lung cancer screening using low dose computed tomography (LDCT) for high-risk individuals identifies early-stage disease and reduces lung cancer mortality.[1,2] Implementation of lung cancer screening is being assessed at scale across England through a Targeted Lung Health Checks (TLHC) programme.[3] One important issue to consider when delivering lung cancer screening is the management of…
Source: Lung CancerCategories: Latest Headlines, Oncologists2Tweet-
Risks and over diagnosis in lung cancer screening need to be analyzed Incidental findings in low dose CT lung cancer screening of high-risk smokers: results from the Manchester Lung Health Check pilot https://t.co/fAGqrbaWGI
-
-
Mashup Score: 2Real-world evidence for immunotherapy in the first line setting in small cell lung cancer - 3 year(s) ago
Small cell lung cancer (SCLC) is an aggressive, rapidly progressing disease accounting for approximately 15% of lung cancers1,2. SCLC is formally staged by the AJCC TNM staging but in the clinic is routinely divided into two categories that influence the treatment recommendations: limited-stage (LS-SCLC) or extensive-stage (ES-SCLC) disease. Approximately 60% of SCLC patients present with…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Real world outcomes of immunotherapy for #SCLC @LungCaJournal showing favorable outcomes even in patients with poor PS, supporting first-line atezolizumab or durvalumab for ES-SCLC. @JairBar4 @ShiraSagie https://t.co/Vte6fiY0ox
-
-
Mashup Score: 4
The fibroblast growth factor receptor (FGFR) pathway plays an important role in tumour pathophysiology by regulating cell proliferation and survival, metastatic spread and angiogenesis [1]. The role of the FGFR tyrosine kinase family as oncogenic drivers is more complex and heterogeneous compared to EGFR, BRAF, ALK, ROS1, NTRK and the likes. FGFR genetic alterations include the most common FGFR3…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
SAKK 19/18 phase II study of rogaratinib in pts with squamous NSCLC expressing #FGFR mRNA now @LungCaJournal. Futility criteria met with only 1 pt reaching 6m PFS (mPFS 1.6m, mOS 3.5m). Toxicity included hyperphosphatemia, diarrhea, stomatitis. @Alfdoc2 https://t.co/FuKnKiDWyx
-
@JackWestMD @RielyMD @n8pennell @ShirishGadgeel @StephenVLiu @JCOPO_ASCO Here's the @DanaFarber squamous NGS experience led by @sands_jacob @lmsholl ⬇️. Once you find an EGFR / ALK / MET in a squamous NSCLC (I've seen each) it's hard to not test at least selectively. Don't need to delay tx, can use it to inform maintenance. https://t.co/Mna6RDrvrj